Albumin-Bound Paclitaxel in Metastatic Carcinoma to the Uterine Cervix: NCT07763496 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Not yet recruiting
Recruitment status
63
Planned enrollment
2030-12-01
Primary-completion proxy
Executive view
NCT07763496 evaluates Albumin-Bound Paclitaxel in Metastatic Carcinoma to the Uterine Cervix. The disclosed sponsor is Arcagy-Gineco, the design is Interventional, and the geographic footprint is France. The first listed primary endpoint is Objective Response Rate (ORR) According to RECIST v1.1, assessed over From the date of first study treatment until documented disease progression, assessed up to 48 months..
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07763496 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Metastatic Carcinoma to the Uterine Cervix landscape. Drug & Asset MCP drug_fetch was queried for Albumin-Bound Paclitaxel, while Company & Deal Intelligence MCP organization_fetch was queried for Arcagy-Gineco.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07763496 | Albumin-Bound Paclitaxel | Phase 2 / Not yet recruiting | Arcagy-Gineco | France | Objective Response Rate (ORR) According to RECIST v1.1 From the date of first study treatment until documented disease progr… | 2030-12-01 |
| PACTR202606770457238 | Lidocaine | Phase 3 / Pending | Sponsor not reported | Nigeria | Timing not reported | |
| NCT07653503 | Nivolumab | Phase 1 / Recruiting | Universitair Medisch Centrum Groningen | Netherlands | Feasibility: Proportion of participants undergoing planned standard surgical treatment after 2 cycles of TDLN-targeted… Through study completion, an average of 2 months per patient | 2027-12-01 |
| NCT07649395 | Recombinant human thrombopoietin (Sunshine Pharmaceutical) | Not Applicable / Completed | Sichuan Cancer Hospital | China | the incidence of severe CTIT (Cancer Treatment-Induced Thrombocytopenia , Grade 3 - Grade 5) 6 months | 2024-06-30 |
| CTRI/2026/06/112765 | Gefitinib | Phase 2 / Not Yet Recruiting | Sponsor not reported | India | Timing not reported |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07763496 is a Phase 2, not yet recruiting study with 63 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Objective Response Rate (ORR) According to RECIST v1.1” over “From the date of first study treatment until documented disease progression, assessed up to 48 months..” The retrieved endpoint description is: Objective Response Rate (ORR) is defined as the proportion of participants with a Complete Response (CR) or Partial Response (PR) as their best overall response according to RECIST version 1.1, based on investigator assessment. Participants with early death, clinical progression, or treatment discontinuation due to toxicity before any tumor assessment will be considered treatment failures. Tumor assessments performed after initiation of subsequent anticancer therapy will not contribute to the ORR assessment..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 63 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
4 recent result records were selected as contextual evidence for Metastatic Carcinoma to the Uterine Cervix. These records do not establish direct evidence for NCT07763496 unless the registration number matches.
Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV
Not Applicable; n=180; Number of Participants Retained in the Study Through Week 24: Risk Difference (RD) = -6.7(95% CI, -14.4 to -0.5); Number of Participants Retained in the Study Through Week 24: Risk Difference (RD) = -6.7(95% CI, -14.4 to -0.5) Source: https://clinicaltrials.gov/ct2/show/results/NCT05413811
Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects With HPV Positive Cancers
Phase 1/2; n=39; Phase I: Recommended Phase II Dose of PRGN-2009 = 500,000,000,000 viral particles (VP) Source: https://clinicaltrials.gov/ct2/show/results/NCT04432597
A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in S…
Phase 1/2; n=175; Phase 2: Objective Response Rate (ORR) - Independent Endpoint Review Committee (IERC) = 26.2 percentage of participants (95% Confidence Interval, 19.7 - 33.9) Source: https://clinicaltrials.gov/ct2/show/results/NCT03495882
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Albumin-Bound Paclitaxel is indexed as Chemical drugs with Tubulin biology and a global stage of Approved. The asset profile lists CSPC Pharmaceutical Group Ltd. as an originator or developer.
Arcagy-Gineco is indexed in France with the website https://arcagy.org. Arcagy-Gineco is a cooperative group that specialized in clinical and translational research in the field of women's cancers. The record lists an unreported number of development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Albumin-Bound Paclitaxel is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07763496
Protocol source: https://clinicaltrials.gov/study/NCT07763496
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Albumin-Bound Paclitaxel in Metastatic Carcinoma to the Uterine Cervix is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Objective Response Rate (ORR) According to RECIST v1.1 and 2030-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
